From January 19, 2026, Ph.D Juris Hmeļņickis will take up the position of Chairman of the Board of the Latvian pharmaceutical manufacturer AS Olpha. Andris Jegorovs, Director of the Production Department, will continue to serve on the company's board. Inga Liščika will also join the board as a member responsible for financial management issues. The current Chairman of the Board Juris Bundulis, will join the AS Olpha Council.
“Several years have passed since the change of ownership at JSC Olpha, and during this time the company has consistently pursued a strategic transformation for development in order to be competitive in the international pharmaceutical market. Under the leadership of Juris Bundulis, a stable foundation has been laid for the company’s new brand, the development of its generic product portfolio, the expansion of exports to Western European markets, and the modernization of production. We thank Juris Bundulis for his contribution to the company’s development and are pleased that he will continue to contribute his experience and knowledge at the strategic management level by serving on the Olpha Board. We expect the new Chairman of the Board to focus on strengthening the company’s efficiency and productivity, as well as further growth in Western export markets,” emphasizes Andrejs Leibovičs, Chairman of the Supervisory Council of JSC Olpha.
“I am honored to join the Olpha team at a time when the company is undergoing active development. Olpha is a company with a strong foundation in pharmaceutical manufacturing and science, long-standing Latvian pharmaceutical traditions, and an ambitious vision for growth in international markets. In the coming years, my task will be to work with the team to strengthen the company’s efficiency, continue investing in the product portfolio and modernization of production, and purposefully develop our presence in international markets. At the same time, it will be important for me to maintain high standards of quality, responsibility and sustainability standards, which are the basis for long-term competitiveness for both the company and the Latvian pharmaceutical industry as a whole,” says Ph.D Juris Hmeļņickis, who will take up the position of Chairman of the Board of JSC “Olpha” on January 19.
Juris Hmeļņickis is an experienced manager with more than 25 years of professional experience in the pharmaceutical industry and drug manufacturing. He has built his professional career at the Latvian pharmaceutical group JSC Grindeks and its subsidiaries, spending the last eight years on the board of JSC Grindeks. Since 2012, he has been a member of the board of JSC Kalceks. At the beginning of his career, he also interned at the German company Merck KGA. Juris Hmeļņickis holds a PhD in chemistry and a master’s degree in economics from the University of Latvia, a master’s degree in quality management from Riga Technical University, and has completed a management program in leadership and sustainable entrepreneurship at the Swedish Institute.
Juris Bundulis has been working in the Latvian pharmaceutical and healthcare industry for more than 30 years. He has worked at the Institute of Organic Synthesis, AS Grindeks, and has held leading positions in the Ministries of Health and Welfare. Juris Bundulis joined Olpha in 2021 as Chairman of the Board, and since September 2022 he has served as Chairman of the Management Board. Juris Bundulis holds an honorary doctorate in biology (Dr.h.c.biol.) from the Latvian Academy of Sciences.
